首页> 外文OA文献 >Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis.
【2h】

Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis.

机译:宫颈癌前病变的不完全切除作为治疗失败的预测因素:系统评价和荟萃分析。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Incomplete excision of cervical precancer is associated with therapeutic failure and is therefore considered as a quality indicator of clinical practice. Conversely, the risk of preterm birth is reported to correlate with size of cervical excision and therefore balancing the risk of adequate treatment with iatrogenic harm is challenging. We reviewed the literature with an aim to reveal whether incomplete excision, reflected by presence of precancerous tissue at the section margins, or post-treatment HPV testing are accurate predictors of treatment failure. METHODS: We did a systematic review and meta-analysis to assess the risk of therapeutic failure associated with the histological status of the margins of the tissue excised to treat cervical precancer. We estimated the accuracy of the margin status to predict occurrence of residual or recurrent high-grade cervical intraepithelial neoplasia of grade two or worse (CIN2+) and compared it with post-treatment high-risk human papillomavirus (HPV) testing. We searched for published systematic reviews and new references from PubMed-MEDLINE, Embase, and CENTRAL and did also a new search spanning the period Jan 1, 1975, until Feb 1, 2016. Studies were eligible if women underwent treatment by excision of a histologically confirmed CIN2+ lesion, with verification of presence or absence of CIN at the resection margins; were tested by cytology or HPV assay between 3 months and 9 months after treatment; and had subsequent follow-up of at least 18 months post-treatment including histological confirmation of the occurrence of CIN2+. Primary endpoints were the proportion of positive section margins and the occurrence of treatment failure associated with the marginal status, in which treatment failure was defined as occurrence of residual or recurrent CIN2+. Information about positive resection margins and subsequent treatment failure was pooled using procedures for meta-analysis of binomial data and analysed using random-effects models. FINDINGS: 97 studies were eligible for inclusion in the meta-analysis and included 44 446 women treated for cervical precancer. The proportion of positive margins was 23·1% (95% CI 20·4-25·9) overall and varied by treatment procedure (ranging from 17·8% [12·9-23·2] for laser conisation to 25·9% [22·3-29·6] for large loop excision of the transformation zone) and increased by the severity of the treated lesion. The overall risk of residual or recurrent CIN2+ was 6·6% (95% CI 4·9-8·4) and was increased with positive compared with negative resection margins (relative risk 4·8, 95% CI 3·2-7·2). The pooled sensitivity and specificity to predict residual or recurrent CIN2+ was 55·8% (95% CI 45·8-65·5) and 84·4% (79·5-88·4), respectively, for the margin status, and 91·0% (82·3-95·5) and 83·8% (77·7-88·7), respectively, for high-risk HPV testing. A negative high-risk HPV test post treatment was associated with a risk of CIN2+ of 0·8%, whereas this risk was 3·7% when margins were free. INTERPRETATION: The risk of residual or recurrent CIN2+ is significantly greater with involved margins on excisional treatment; however, high-risk HPV post-treatment predicts treatment failure more accurately than margin status. FUNDING: European Federation for Colposcopy and Institut national du Cancer (INCA).
机译:背景:宫颈癌的不完全切除与治疗失败有关,因此被认为是临床实践的质量指标。相反,据报道早产的风险与宫颈切除术的大小有关,因此,在适当治疗的风险与医源性伤害之间取得平衡是一项挑战。我们回顾了文献,目的是揭示不完整的切除(由切缘癌前组织的存在反映出来)还是治疗后的HPV检测是否是治疗失败的准确预测指标。方法:我们进行了系统的回顾和荟萃分析,以评估与治疗宫颈癌前体组织切缘的组织学状态相关的治疗失败的风险。我们估计了边缘状态的准确性,以预测是否发生残留或复发的二级或更严重的高度宫颈上皮内瘤变(CIN2 +),并将其与治疗后的高危人乳头瘤病毒(HPV)检测进行比较。我们从PubMed-MEDLINE,Embase和CENTRAL搜索了已发表的系统评价和新参考文献,还进行了一次新的搜索,搜索时间跨度为1975年1月1日至2016年2月1日。如果女性通过组织学切除术进行了治疗,则这些研究是合格的确认为CIN2 +病变,并确认切除边缘是否存在CIN;在治疗后3个月至9个月内通过细胞学或HPV检测进行检测;并在治疗后至少18个月进行了后续随访,包括组织学证实CIN2 +的发生。主要终点为阳性切缘的比例和与边缘状态相关的治疗失败的发生,其中治疗失败的定义为发生残留或复发的CIN2 +。使用二项式数据的荟萃分析程序收集有关阳性切除切缘和后续治疗失败的信息,并使用随机效应模型进行分析。结果:97项研究符合纳入荟萃分析的条件,纳入了44至446名接受宫颈癌前期治疗的女性。阳性切缘的比例总体为23·1%(95%CI 20·4-25·9),并随治疗程序的不同而变化(从激光锥切术的17·8%[12·9-23·2]到25· 9%[22·3-29·6]用于大面积切除转化区,并因治疗病变的严重程度而增加。残留或复发性CIN2 +的总风险为6·6%(95%CI 4·9-8·4),与阴性切除切缘相比,阳性风险增加(相对风险4·8,95%CI 3·2-7) ·2)。对于边缘状态,预测残留或复发性CIN2 +的综合敏感性和特异性分别为55·8%(95%CI 45·8-65·5)和84·4%(79·5-88·4),高危HPV检测分别为91.0%(82·3-95·5)和83·8%(77·7-88·7)。治疗后阴性高危HPV检测与CIN2 +的风险为0·8%,而无余量的风险为3·7%。解释:切除治疗涉及切缘时,残留或复发性CIN2 +的风险明显更高;但是,高危HPV后处理比边缘状态更能准确预测治疗失败。资金:欧洲阴道镜和国家癌症研究所联合会(INCA)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号